US biosimilars legislation could take some time to approve, meeting hears
This article was originally published in SRA
Executive Summary
The new political environment in Washington, DC, is favourable towards biosimilars, but getting US biosimilars legislation approved is still likely to be a long haul. This was the message from Juliana Reed, director of the Office of Government Affairs at global pharma and medication delivery company Hospira, who spoke at a meeting on 23-24 April in London that was organised by the European Generic medicines Association.